GCM
Gladius Capital Management Portfolio holdings
AUM
$63.8M
1-Year Return
3.49%
This Quarter Return
+0.52%
1 Year Return
+3.49%
3 Year Return
+10.82%
5 Year Return
+16.08%
10 Year Return
+49.7%
AUM
$200M
AUM Growth
-$125M
(-39%)
Cap. Flow
-$141M
Cap. Flow
% of AUM
-70.59%
Top 10 Holdings %
Top 10 Hldgs %
83.33%
Holding
406
New
99
Increased
74
Reduced
99
Closed
109
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
$6.37M |
| 2 |
Alphabet (Google) Class C
GOOG
|
$3.04M |
| 3 |
Coca-Cola
KO
|
$2.97M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$2.32M |
| 5 |
Verisk Analytics
VRSK
|
$994K |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$58.6M |
| 2 |
iShares MSCI EAFE ETF
EFA
|
$26.7M |
| 3 |
Invesco QQQ Trust
QQQ
|
$16.4M |
| 4 |
Walmart
WMT
|
$7.48M |
| 5 |
JPMorgan Chase
JPM
|
$6.72M |
Sector Composition
| 1 | Healthcare | 6.61% |
| 2 | Technology | 4.38% |
| 3 | Industrials | 3.16% |
| 4 | Communication Services | 2.89% |
| 5 | Consumer Staples | 2.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
John B. Sanfilippo & Son
JBSS
$751M
| $23.9K | ﹤0.01% |
+204
| New | +$23.9K |
|
202
Emerald Holding
EEX
$1.07B
| $23.8K | ﹤0.01% |
+5,803
| New | +$23.8K |
|
203
Build-A-Bear
BBW
$812M
| $23.7K | ﹤0.01% |
1,108
-412
| -27% | -$8.83K |
|
204
World Kinect Corp
WKC
$1.47B
| $23.7K | ﹤0.01% |
+1,145
| New | +$23.7K |
|
205
Nuvation Bio
NUVB
$1.37B
| $23.2K | ﹤0.01% |
12,884
-1,418
| -10% | -$2.55K |
|
206
Collegium Pharmaceutical
COLL
$1.23B
| $22.9K | ﹤0.01% |
1,067
-168
| -14% | -$3.61K |
|
207
Orthofix Medical
OFIX
$579M
| $22.8K | ﹤0.01% |
1,263
-470
| -27% | -$8.49K |
|
208
Universal Corp
UVV
$1.36B
| $22.6K | ﹤0.01% |
452
-222
| -33% | -$11.1K |
|
209
Lyell Immunopharma
LYEL
$231M
| $22.1K | ﹤0.01% |
348
-202
| -37% | -$12.8K |
|
210
AnaptysBio
ANAB
$606M
| $22K | ﹤0.01% |
+1,082
| New | +$22K |
|
|
EQRX
211
DELISTED
EQRx, Inc. Common Stock
EQRX
| $21.6K | ﹤0.01% |
11,607
-2,866
| -20% | -$5.33K |
|
212
Supernus Pharmaceuticals
SUPN
$2.58B
| $21.5K | ﹤0.01% |
+715
| New | +$21.5K |
|
213
SIGA Technologies
SIGA
$599M
| $21.1K | ﹤0.01% |
4,181
-749
| -15% | -$3.78K |
|
214
Ambac
AMBC
$421M
| $21K | ﹤0.01% |
+1,476
| New | +$21K |
|
215
Bio-Rad Laboratories Class A
BIO
$7.91B
| $20.8K | ﹤0.01% |
+55
| New | +$20.8K |
|
|
AAN
216
DELISTED
The Aaron's Company, Inc.
AAN
| $20.4K | ﹤0.01% |
1,446
-1,482
| -51% | -$21K |
|
217
Century Therapeutics
IPSC
$42.4M
| $19.7K | ﹤0.01% |
6,246
-1,484
| -19% | -$4.69K |
|
218
Moderna
MRNA
$9.71B
| $19.7K | ﹤0.01% |
+162
| New | +$19.7K |
|
219
Nektar Therapeutics
NKTR
$695M
| $19.6K | ﹤0.01% |
+2,276
| New | +$19.6K |
|
220
Cartesian Therapeutics
RNAC
$270M
| $19.2K | ﹤0.01% |
+571
| New | +$19.2K |
|
221
Alta Equipment Group
ALTG
$267M
| $18.9K | ﹤0.01% |
1,090
-1,105
| -50% | -$19.2K |
|
222
Emergent Biosolutions
EBS
$406M
| $18.3K | ﹤0.01% |
2,492
-217
| -8% | -$1.6K |
|
223
ODP
ODP
$650M
| $17.4K | ﹤0.01% |
+371
| New | +$17.4K |
|
|
ITOS
224
DELISTED
iTeos Therapeutics
ITOS
| $17.1K | ﹤0.01% |
1,292
-424
| -25% | -$5.61K |
|
225
Atea Pharmaceuticals
AVIR
$265M
| $16.2K | ﹤0.01% |
4,330
-3,383
| -44% | -$12.7K |
|